VIVUS Inc

VIVUS — Technical Presentation (May 2011)

15 slides from VIVUS's technical presentation, May 24, 2011

  1. Slide 1: Evaluation of Cardiovascular Effects in Three Double-Blind, Placebo-Controlled Clinical Trials with PHEN/TPM CR

    Suzanne Oparil, MD Dept of Medicine-Cardiovascular Disease, University of Alabama, Birmingham, AL, USA, 35294 Wesley W. Day, PhD Charles Bowden, MD Vivus Inc, Mountain View, CA, USA, 94040 Evaluation of Cardiovascular Effects in Three Double-Blind, Placebo-Controlled Clinical Trials with Controlled-

  2. Slide 2: Author Disclosure

    Author Disclosure Past 12 months Suzanne Oparil, MD Grant/Research Support: Amgen Inc., and Merck and Co. Consultant/Advisory Board: Boehringer-Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Forest Laboratories, NicOx, Novartis, Vivus, and Omron Healthcare Speakers Bureau: Daiichi Sankyo Inc., and Novar

  3. Slide 3: Introduction

    Introduction Data represents a pooled evaluation of cardiovascular effects from three 56-week, randomized, double-blind, placebo-controlled clinical trials for weight loss with controlled-release phentermine/topiramate (PHEN/TPM CR) Pre-specified evaluations: Weight loss over time Blood pressure and

  4. Slide 4: PHEN/TPM CR

    PHEN/TPM CR PHEN/TPM CR is a fixed-dose combination under investigation for the treatment of weight loss1 PHEN (Phentermine hydrochloride) is a sympathomimetic amine, an anorectic agent, approved by the FDA at 37.5 mg/day as a short-term therapeutic adjunct to a weight loss regimen2 TPM (Topiramate)

  5. Slide 5: Study Designs

    Study Designs OB-302 (EQUIP): 56-week, phase 3 trial of PHEN/TPM CR in adults with Body Mass Index (BMI) >35 kg/m2 Placebo (n=513) PHEN/TPM CR 3.75/23 (n=240) PHEN/TPM CR 15/92 (n=511) OB-303 (CONQUER): 56-week, phase 3 trial of PHEN/TPM CR in adults with BMI >27 kg/m2 and <45 kg/m2 and >2 obesity-r

  6. Slide 6: Obesity Clinical Study Design

    Obesity Clinical Study Design Titration (4 weeks) Treatment (52 weeks) EQUIP/CONQUER/DM-230 PHEN/TPM CR 15/92 (safety set data, n= 1580) PHEN/TPM CR 3.75/23 (safety set data, n= 240) Placebo (safety set data, n= 1561) 0 2 4 12 8 16 20 24 32 28 36 40 44 48 56 52 Screening (2 weeks) PHEN/TPM CR 7.5/46

  7. Slide 7: Percent Weight Loss From Baseline

    Percent Weight Loss From Baseline to 56 weeks† *P<0.0001 vs placebo †Based on ITT-LOCF data from studies OB-302 and OB-303

  8. Slide 8: Change in Blood Pressure and Heart Rate at Week 56

    Change in Blood Pressure and Heart Rate at Week 56 (Safety set) The cardiovascular effects analysis includes subjects with baseline and endpoint measurements. In the CONQUER study (Gadde, K, et al. 2011,The Lancet, 377: 1341-1352): 5% of the placebo group had their antihypertensive drugs withdrawn 1

  9. Slide 9: Change in Blood Pressure: Hypertensive and Non-Hypertensive Subgroups

    Change in Blood Pressure at Week 56 Hypertensive and Non-Hypertensive Subgroups (Safety set)

  10. Slide 10: Change in Heart Rate by Baseline Heart Rate Category

    Change in Heart Rate by Baseline Heart Rate Category (Safety set)

  11. Slide 11: Consecutive Categorical Increases in Blood Pressure and Heart Rate

    Consecutive Categorical Increases in Blood Pressure and Heart Rate (Safety set) The data summarizes the percentages of subjects in the 1-year cohort with consecutive categorical increases in SBP, DBP, and heart rate, defined as two or more consecutive measures above the given threshold, during the d

  12. Slide 12: Change in Rate Pressure Product at Week 56

    Change in Rate Pressure Product at Week 56 (Safety set) LS mean reductions in RPP were observed in all treatment group with no significant differences detected at Week 56

  13. Slide 13: Treatment-Emergent Adverse Events by Preferred Term

    Preferred Term, n (%) Placebo (n=1561) PHEN/TPM CR 3.75/23 (n=240) PHEN/TPM CR 7.5/46 (n=498) PHEN/TPM CR 15/92 (n=1580) Paresthesia 30 (1.9) 10 (4.2) 68 (13.7) 315 (19.9) Dry mouth 43 (2.8) 16 (6.7) 67 (13.5) 301 (19.1) Constipation 96 (6.1) 19 (7.9) 75 (15.1) 255 (16.1) Headache 145 (9.3) 25 (10.4

  14. Slide 14: Conclusions

    Conclusions PHEN/TPM CR demonstrated significant weight loss in obese individuals that appeared to correlate with improvement in several cardiovascular parameters Reductions in SBP and DBP were seen at all doses of PHEN/TPM CR; with reduction in antihypertensive medications in the two higher doses D

  15. Slide 15: Acknowledgements

    Acknowledgements We would like to thank the PHEN/TPM CR study participants, the site staff and investigators We acknowledge assistance developing the slides from Peter Hughes, PhD and Barbara Troupin, MD, from Vivus; and graphics development assistance from the Lockwood Group

VIVUS — Technical Presentation (May 2011) on 6ix